Research programme: muscarinic receptor agonists and antagonists - ACADIA/Sepracor

Drug Profile

Research programme: muscarinic receptor agonists and antagonists - ACADIA/Sepracor

Alternative Names: 108LM39-36; AC 90987; AC-260584

Latest Information Update: 26 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ACADIA Pharmaceuticals; Sepracor
  • Class
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders; Cognition disorders; Neuropathic pain; Psychotic disorders; Schizophrenia

Most Recent Events

  • 21 Jan 2005 ACADIA and Sepracor entered into an agreement to jointly develop therapeutic agents for the treatment of CNS disorders
  • 04 Aug 2004 Preclinical trials in Schizophrenia in USA (unspecified route)
  • 07 Apr 2003 Data presented at the 225th American Chemical Society Meeting (225th-ACS) have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top